Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
1 hedge funds and large institutions have $6.67K invested in Nymox Pharmaceutical Corp in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
67% less funds holding
Funds holding: 3 → 1 (-2)
86% less capital invested
Capital invested by funds: $48K → $6.67K (-$41.4K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DDC
DF Dent & Co
Baltimore,
Maryland
|
-$30K |
NYMX Hedge Fund Activity: Q2 2024 in Review
1 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q2 2024, worth a combined $6.67K — down 86% from $48K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of NYMX and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was DF Dent & Co, exiting entirely with an estimated $30K sold.
- 1 institutional investor held Nymox Pharmaceutical Corp (NYMX) as of Q2 2024, down from 3 in Q1 2024.
- Funds reported $6.67K of Nymox Pharmaceutical Corp stock for Q2 2024, down 86% quarter-over-quarter.
- 0 funds opened new Nymox Pharmaceutical Corp positions in Q2 2024 and 1 closed out, a net change of -1 holder.
- The largest Nymox Pharmaceutical Corp seller in Q2 2024 was DF Dent & Co, an estimated $30K sold.
Based on aggregated 13F filings for Q2 2024.